Log in

Relevant bibliographies by topics / Relapse / Journal articles

To see the other types of publications on this topic, follow the link: Relapse.

Journal articles on the topic 'Relapse'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Relapse.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wudhikarn, Kitsada, Pinyo Rattanaumpawan, and Margarida M. Silverman. "Characterization of Extramedullary Relapse After Allogeneic Stem Cell Transplant in Acute Myeloblastic Leukemia: Distinct Entity and Outcome." Blood 120, no. 21 (2012): 1972. http://dx.doi.org/10.1182/blood.v120.21.1972.1972.

Full text

Abstract:

Abstract Abstract 1972 Introduction: Relapse after allogeneic stem cell transplant (SCT) is a major cause of morbidity and mortality of acute myeloblastic leukemia (AML) patients. Most relapses primarily involve bone marrow whereas extramedullary (EM) relapses are relatively uncommon. Data on natural history, optimal management and treatment outcome in EM relapse following allogeneic SCT are limited. Method: We retrospectively reviewed 130 AML patients who underwent allogeneic SCT at the University of Iowa Hospitals and Clinics between January 2003 and December 2010. Pre-transplant baseline ch

APA, Harvard, Vancouver, ISO, and other styles

2

Wang, Yucai, Umar Farooq, Brian K. Link, et al. "Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy." Journal of Clinical Oncology 37, no. 21 (2019): 1819–27. http://dx.doi.org/10.1200/jco.19.00014.

Full text

Abstract:

PURPOSE In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur within the first 2 years of diagnosis. We sought to define the rate and outcome of late relapses that occurred after achieving event-free survival at 24 months (EFS24). METHODS We prospectively followed 1,324 patients with newly diagnosed DLBCL from 2002 to 2015 and treated with immunochemotherapy. Cumulative incidences of late DLBCL and indolent lymphoma relapses were analyzed as competing events. Postrelapse survival was defined as time from first relapse to death from any cause. RESULTS In 847 patients who a

APA, Harvard, Vancouver, ISO, and other styles

3

Ganzel, Chezi, Wang Xin Victoria, Adele K. Fielding, et al. "in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993." Blood 126, no. 23 (2015): 795. http://dx.doi.org/10.1182/blood.v126.23.795.795.

Full text

Abstract:

Abstract This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and the Medical Research Counsel, United Kingdom, and supported in part by Public Health Service Grants CA180820, CA180794, CA180790, CA189859, CA180853, CA180791, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Background: Late relapse

APA, Harvard, Vancouver, ISO, and other styles

4

Platte, Victoria, Anika Bergmann, Barbara Hildebrandt, et al. "Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component." Cancers 14, no. 24 (2022): 6244. http://dx.doi.org/10.3390/cancers14246244.

Full text

Abstract:

An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related factors, including karyotype analyses at diagnosis and relapse. After a median follow-up of 17.4 mon

APA, Harvard, Vancouver, ISO, and other styles

5

Stolpa, Weronika, Magdalena Zapała, Bartosz Zwiernik, and Agnieszka Mizia-Malarz. "Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience." Children 9, no. 12 (2022): 1874. http://dx.doi.org/10.3390/children9121874.

Full text

Abstract:

The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125 pediatric patients with ALL diagnosed in our department between 2000-2018; age 1–18 years old (median 6.4); female 53.6 % vs. male 46.4 %. Results: 19 pts (15.2%) were diagnosed with a relapse. Three pts (15.8%) had been diagnosed with very early relapses (2/3 T-ALL), 12 pts (63.1%) as an early rela

APA, Harvard, Vancouver, ISO, and other styles

6

Nagane, Motoo, Nobuyoshi Sasaki, Yuki Yamagaishi, Kuniaki Saito, Keiichi Kobayashi, and Hirofumi Nakatomi. "CTNI-81. REAL-WORLD TREATMENT RESULTS OF RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATED BY MEDICAL THERAPIES." Neuro-Oncology 25, Supplement_5 (2023): v96—v97. http://dx.doi.org/10.1093/neuonc/noad179.0363.

Full text

Abstract:

Abstract Recurrence of primary central nervous system lymphoma (PCNSL) is a condition which often leads to morbidity and mortality. Consensus regarding the optimal treatment regimen for relapsed PCNSL has not been achieved due to the rarity of the disease. In this study, we conducted a retrospective, single-institution study to investigate real world treatment results of relapsed PCNSL treated by several medical therapeutic regimens. Relapsed PCNSL patients treated at the authors’ institution were identified, and progression-free survival (PFS), overall survival (OS) were analyzed among patien

APA, Harvard, Vancouver, ISO, and other styles

7

Barz, Malwine J., Jana Hof, Stefanie Groeneveld-Krentz, et al. "Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia." Blood 135, no. 12 (2020): 921–33. http://dx.doi.org/10.1182/blood.2019002499.

Full text

Abstract:

Abstract Activating mutations in cytosolic 5′-nucleotidase II (NT5C2) are considered to drive relapse formation in acute lymphoblastic leukemia (ALL) by conferring purine analog resistance. To examine the clinical effects of NT5C2 mutations in relapsed ALL, we analyzed NT5C2 in 455 relapsed B-cell precursor ALL patients treated within the ALL-REZ BFM 2002 relapse trial using sequencing and sensitive allele-specific real-time polymerase chain reaction. We detected 110 NT5C2 mutations in 75 (16.5%) of 455 B-cell precursor ALL relapses. Two-thirds of relapses harbored subclonal mutations and only

APA, Harvard, Vancouver, ISO, and other styles

8

Abu Shanap, Mayada, and Iyad Sultan. "Outcome of Relapsed Childhood Acute Lymphoblastic Leukemia in Resource-Poor Country : Warrants the Need for Immunotherapy." Blood 144, Supplement 1 (2024): 5857. https://doi.org/10.1182/blood-2024-206147.

Full text

Abstract:

Introduction: The overall survival (OS) rate for children with acute lymphoblastic leukemia (ALL) treated at King Hussein Cancer Center is approximately 80%, aligning with published results of the Total XV regimen. Method: From December 2003 until August 2023, children/adolescents (&lt;18 years at diagnosis) with ALL in first and subsequent relapses were studied. Treatment of relapse consisted of reinduction regimens followed by intensive continuation therapy and hematopoietic stem cell transplantation (HSCT) in selected patients. The poor prognostic group (PPG) included patients who did n

APA, Harvard, Vancouver, ISO, and other styles

9

Maxwell, Rebecca, Beate Häberle, Roland Kappler, et al. "Hepatoblastoma Relapse—Findings from the German HB99 Trial and the German Liver Tumor Registry." Cancers 16, no. 4 (2024): 696. http://dx.doi.org/10.3390/cancers16040696.

Full text

Abstract:

Survival rates for HB patients have improved; however, outcomes for patients who relapse remain poor. A retrospective review of information gathered for the HB99 study and the German Liver Tumor Registry identified 25 relapse patients (6.9%, 25/362). The median time from initial diagnosis to first relapse was 13 months (range: 5–66 months). Two patients relapsed >36 months after initial diagnosis. A total of 68% (17/25) of relapses were metastatic, 24% local, and 8% combined. 67% of local relapses were alive at the last follow-up, in contrast to 53% of metastatic and 0% of combined relapses

APA, Harvard, Vancouver, ISO, and other styles

10

Hill, Rebecca, Stacey Richardson, Edward Schwalbe, et al. "MBRS-44. TIME, PATTERN AND OUTCOME OF MEDULLOBLASTOMA RELAPSE ARE ASSOCIATED WITH TUMOUR BIOLOGY AT DIAGNOSIS AND UPFRONT THERAPY: A COHORT STUDY." Neuro-Oncology 22, Supplement_3 (2020): iii405—iii406. http://dx.doi.org/10.1093/neuonc/noaa222.553.

Full text

Abstract:

Abstract Disease relapse occurs in ~30% of children with medulloblastoma, and is fatal in the majority. We sought to establish whether clinico-molecular characteristics at diagnosis are associated with the nature of relapse, subsequent disease-course, and whether these associations could inform clinical management. We surveyed the clinical features of medulloblastoma relapse (time-to-relapse, pattern-of-relapse, time-to-death and overall outcome) in 247 centrally-reviewed patients who relapsed following standard-upfront-therapies. We related these to clinico-molecular features at diagnosis, pr

APA, Harvard, Vancouver, ISO, and other styles

11

Bellavance, Caroline, Virgile Raufaste-Cazavieille, Felix-Antoine Trifiro, et al. "Multi-omics evaluation of relapsed pediatric cancers: What information do these sequential analyses yield?" Journal of Clinical Oncology 43, no. 16_suppl (2025): 10047. https://doi.org/10.1200/jco.2025.43.16_suppl.10047.

Full text

Abstract:

10047 Background: While cure rates for children with cancer have significantly improved, relapses remain a challenge, requiring deeper understanding to address them. Nowadays, genomic analyses are widely used at diagnosis and in relapse settings, becoming a standard-of-care in pediatric. The aim of this study is to describe the genomic evolution of relapsed pediatric tumors in search of clonal selection and pathway identification. We also want to assess the clinical value of these new data obtained in relapsed tumors. Methods: This is a retrospective analysis from canadian pediatric oncology p

APA, Harvard, Vancouver, ISO, and other styles

12

Kelaidi, C., L. Ades, S. Chevret, et al. "Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials)." Blood 106, no. 11 (2005): 890. http://dx.doi.org/10.1182/blood.v106.11.890.890.

Full text

Abstract:

Abstract The routine use of frontline ATRA and anthracycline-based chemotherapy has greatly improved the outcome of APL, particularly by reducing the incidence of relapses, notably early relapses. The incidence and characteristics of late relapses after this combined treatment, however, are not known. Methods: Between 1991 and 1997 (APL 91 and 93 trials) 630 newly diagnosed APL pts received ATRA combined to or followed by DNR-AraC chemotherapy (total of 3 courses), with or without (randomisation) maintenance treatment by continuous 6MP + MTX and/or intermittent ATRA (Blood1993; 82:3241–3249, B

APA, Harvard, Vancouver, ISO, and other styles

13

Li, Benshang, Yongjin Li, Shuhong Shen, et al. "Mutational Landscape and Temporal Evolution during Treatment of Relapsed Acute Lymphoblastic Leukemia." Blood 132, Supplement 1 (2018): 917. http://dx.doi.org/10.1182/blood-2018-99-119144.

Full text

Abstract:

Abstract Introduction Relapsed childhood acute lymphoblastic leukemia (ALL) is a leading cause of cancer-related death in children and has poor prognosis due to acquired drug resistance. However, the clonal evolution leading to drug resistance at ALL relapse is incompletely understood. Methods We performed whole-genome sequencing (WGS) of samples at diagnosis and relapse from 103 Chinese patients, most of whom were enrolled on the Shanghai Children's Medical Center (SCMC) ALL2005 frontline treatment protocol. We also performed ultra-deep sequencing at 5,000-50,000X coverage of 211 serial bone-

APA, Harvard, Vancouver, ISO, and other styles

14

Johnson, Kristina K., Deirdra R. Terrell, Bernhard Lammle, Johanna Kremer Hovinga, James N. George, and Sara K. Vesely. "Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP)." Blood 108, no. 11 (2006): 91. http://dx.doi.org/10.1182/blood.v108.11.91.91.

Full text

Abstract:

Abstract The greatest concern for patients who have recovered from an acute episode of TTP is the risk for relapse. We have analyzed the experience of The Oklahoma TTP-HUS Registry to estimate the risk for relapse and to identify the time to relapse and factors that determine the risk for relapse. The Registry has complete follow-up data on 333 of 335 consecutive patients who had their first episode of clinically diagnosed TTP, 1989–2005. Patients who were discovered to have an alternative diagnosis for their signs of TTP, patients whose TTP followed bone marrow transplantation and patients wi

APA, Harvard, Vancouver, ISO, and other styles

15

Rheingold, Susan R., Lingyun Ji, Xinxin Xu, et al. "Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study." Journal of Clinical Oncology 37, no. 15_suppl (2019): 10008. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10008.

Full text

Abstract:

10008 Background: Survival of pediatric ALL patients (pts) now approaches 90%, but is historically poor for those who relapse. Methods: In the largest cohort assembled to date we analyzed overall survival (OS) rate post relapse, defined as duration between date of relapse and death, among pts diagnosed from 1996-2014 treated on 10 contemporary COG frontline trials. Comparisons of post-relapse OS were based on logrank tests, with two-sided p values reported. Results: Of 15,874 pts enrolled on frontline trials, 1,967(12%) relapsed. Relapse rates ranged from 35% in infant ALL to 9.7% in pts with

APA, Harvard, Vancouver, ISO, and other styles

16

Hamilton, Robert J., Madhur Nayan, Lynn Anson-Cartwright, et al. "Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance." Journal of Clinical Oncology 37, no. 22 (2019): 1919–26. http://dx.doi.org/10.1200/jco.18.01250.

Full text

Abstract:

PURPOSE Active surveillance (AS) for testicular nonseminomatous germ cell tumors (NSGCT) is widely used. Although there is no consensus for optimal treatment at relapse on surveillance, globally patients typically receive chemotherapy. We describe treatment of relapses in our non–risk-adapted NSGCT AS cohort and highlight selective use of primary retroperitoneal lymph node dissection (RPLND). METHODS From December 1980 to December 2015, 580 patients with clinical stage I NSGCT were treated with AS, and 162 subsequently relapsed. First-line treatment was based on relapse site and extent. Logist

APA, Harvard, Vancouver, ISO, and other styles

17

Rajkumar, Prabu, Girish Kumar Chethrapilly Purushothaman, Manickam Ponnaiah, et al. "Low risk of relapse and deformity among leprosy patients who completed multi-drug therapy regimen from 2005 to 2010: A cohort study from four districts in South India." PLOS Neglected Tropical Diseases 15, no. 11 (2021): e0009950. http://dx.doi.org/10.1371/journal.pntd.0009950.

Full text

Abstract:

Introduction Relapse of leprosy among patients released from treatment (RFT) is an indicator of the success of anti-leprosy treatment. Due to inadequate follow-up, relapse in leprosy patients after RFT is not systematically documented in India. Relapsed leprosy patients pose a risk in the transmission of leprosy bacilli. We determined the incidence of relapse and deformity among the patients RFT from the leprosy control programme in four districts in South India. Methods We conducted two follow-up surveys in 2012 and 2014 among the leprosy patients RFT between 2005 and 2010. We assessed them f

APA, Harvard, Vancouver, ISO, and other styles

18

Ríos-Garcés, R., J. Hernández-Rodríguez, S. Prieto-González, M. C. Cid, and G. Espígol-Frigolé. "AB0763 CHARACTERISTICS OF RELAPSES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. A SINGLE CENTRE EXPERIENCE." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1588. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2850.

Full text

Abstract:

BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a heterogeneous disease with a variable, relapsing course. Real-world data regarding specific characteristics of relapses in this patients are scarce.ObjectivesWe aim to describe and analyse the relapses presented in a single-center cohort of EGPA patients.MethodsMedical charts of EGPA patients regularly controlled at our department were reviewed to describe demographics, clinical characteristics at diagnosis and at relapse, number of relapses, disease activity at relapse, treatment of the relapses, damage accrual, and laborator

APA, Harvard, Vancouver, ISO, and other styles

19

Fonseca, Adriana, Cecile Faure-Conter, Matthew Murray, et al. "The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials." Journal of Clinical Oncology 38, no. 15_suppl (2020): 2503. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2503.

Full text

Abstract:

2503 Background: CNS-NGGCT are rare tumors that have been successfully treated with multimodal therapies. With a 5-yr EFS and OS of 72-84% and 82-93% respectively, surveillance and relapse detection is essential. Tumor marker (TM) elevation has proven to be a highly sensitive method of relapse detection in extra-cranial-NGGCT. We aim to determine the role of TM for relapse surveillance in children and adolescents with CNS-NGGCTs. Methods: European and North American data from germ cell tumor trials (SIOP GCT96, SFOP-TGM TC 90/92, COG-ACNS0122 and COG-ACNS1123) were pooled for analysis. Additio

APA, Harvard, Vancouver, ISO, and other styles

20

Blum, William, Sam Penza, Sherif Farag, et al. "Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens." Blood 104, no. 11 (2004): 5123. http://dx.doi.org/10.1182/blood.v104.11.5123.5123.

Full text

Abstract:

Abstract Rates of extramedullary relapse are reported to be more than twice as high following transplantation with busulfan-based conditioning regimens (Simpson et al, Bone Marrow Transplantation 1998, Lee et al, Bone Marrow Transplantation 2000) compared to total body irradiation (TBI)-based regimens (Mortimer et al, J. Clin Oncol 1989) in acute myeloid leukemia (AML). Up to 50% of relapses following transplantation with busulfan-based therapies are reported to be extramedullary, with more than 25% as isolated extramedullary relapses. We analyzed 228 consecutive AML patients who underwent all

APA, Harvard, Vancouver, ISO, and other styles

21

Florvall, Cecilia, Peder Frederiksen, Jakob Lauritsen, et al. "Relapse and Mortality Risk of Stage I Testicular Cancer." Journal of Insurance Medicine 47, no. 2 (2017): 114–24. http://dx.doi.org/10.17849/insm-47-02-114-124.1.

Full text

Abstract:

Objectives. – To assess the medical insurance risk for patients with stage I testicular cancer (TC), by calculating the overall mortality risk with and without relapse, and compare it to men from the Danish population. Background. – Testicular cancer is the most common malignancy in young males. Outcomes of a Danish cohort of 3366 patients with stage I TC (1366 non-seminomas (NSTC) and 2000 Seminomas (STC)), were analyzed. Method. – The data were analyzed by the “illness-death” model. For the analysis of the transitions between diagnosis, relapse and death we adopted a parametric approach, whe

APA, Harvard, Vancouver, ISO, and other styles

22

Hansen, M., and C. Hahn. "P.004 Autoimmune Encephalitis: Modifiable and Non-Modifiable Predictors of Relapse." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 48, s3 (2021): S21. http://dx.doi.org/10.1017/cjn.2021.287.

Full text

Abstract:

Background: Approximately 25% of encephalitis cases in North America are immune mediated. For most forms of autoimmune encephalitis (AIE), risk of relapse is unclear and little evidence exists to guide which patients have the highest risk and whether standard treatments reduce this risk. Our objective was to determine the factors associated with AIE relapse. Methods: We performed a chart review consisting of patients with AIE presenting to the Calgary Neuro-Immunology Clinic and Tom Baker Cancer Centre between 2015 and 2020. Predictors of relapse were determined with use of t-test. Results: Ou

APA, Harvard, Vancouver, ISO, and other styles

23

Kumar, Prashanth, Nisha Joseph, Dhwani Almaula, et al. "Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant." Blood 128, no. 22 (2016): 4524. http://dx.doi.org/10.1182/blood.v128.22.4524.4524.

Full text

Abstract:

Abstract Introduction: In younger patients that are transplant-eligible, autologous stem cell transplant (ASCT) prolongs overall survival based on several prospective randomized control trials. Nevertheless, ASCT is not a curative approach and majority of the patient's relapse, requiring further salvage therapeutic options. However, in the face of an ongoing paradigm shift in myeloma therapeutics, there is a significant knowledge gap regarding how patients relapse following ASCT. We analyzed the patterns of relapse among myeloma patients after ASCT. Methodology: We have evaluated a total of 97

APA, Harvard, Vancouver, ISO, and other styles

24

Muirhead, Rebecca, Lisa Durrant, Katherine Hyde, and Maria Hawkins. "Volumetric analysis of anal cancer relapses following radical chemoradiation." Journal of Clinical Oncology 32, no. 3_suppl (2014): 576. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.576.

Full text

Abstract:

576 Background: Definitive chemoradiotherapy is standard of care in anal squamous cell carcinoma. The ACT II trial set the standard achieving three year overall survival rates of 73%. However patients with locally advanced disease have a ~50% local relapse rate. Studies have failed to demonstrate an improvement in local relapse rate by altering the systemic therapy. Although 2/3 of relapses are local as opposed to regional or distant, there is limited knowledge on the 3D position of these relapses. We aim to retrospectively review the patterns of local failure in three dimensions, relative to

APA, Harvard, Vancouver, ISO, and other styles

25

Kaspers, Gertjan, Martin Zimmermann, Dirk Reinhardt, et al. "Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01." Blood 116, no. 21 (2010): 184. http://dx.doi.org/10.1182/blood.v116.21.184.184.

Full text

Abstract:

Abstract Abstract 184 Acute Myeloid Leukemia - Therapy, excluding Transplantation: Pediatric and Adult AML Therapy Introduction: With improving initial antileukemic therapy, CNS disease might become more important in AML. We therefore evaluated the incidence of CNS involvement in a large series of children with first relapsed AML. In addition, clinical and biological features of children with and without CNS involvement at relapse were compared, and finally the prognostic significance of CNS involvement at relapse was studied. Materials and Methods: Patients were selected from those registered

APA, Harvard, Vancouver, ISO, and other styles

26

Cohen, Jonathon B., Madhusmita Behera, Carrie A. Thompson, and Christopher R. Flowers. "Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma." Blood 129, no. 5 (2017): 561–64. http://dx.doi.org/10.1182/blood-2016-08-685073.

Full text

Abstract:

Abstract Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well defined. We evaluated the surveillance imaging role in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival.

APA, Harvard, Vancouver, ISO, and other styles

27

Tringale, Kathryn, Joachim Yahalom, Michael Scordo, et al. "NIMG-98. IDENTIFYING PATTERNS OF FAILURE AFTER INITIAL THERAPY IN PRIMARY CNS LYMPHOMA IN A LARGE PATIENT COHORT." Neuro-Oncology 24, Supplement_7 (2022): vii187—vii188. http://dx.doi.org/10.1093/neuonc/noac209.716.

Full text

Abstract:

Abstract INTRODUCTION Treatment of primary CNS lymphoma (PCNSL) has rapidly evolved, emphasizing improved efficacy while reducing neurotoxicity. PCNSL has historically been considered a multifocal disease and many patients relapse after first-line therapy. We evaluated relapse patterns in a large cohort of contemporarily treated patients. METHODS Consecutive PCNSL patients treated at MSKCC between 1983-2020 were analyzed. T1 post-contrast-enhancing disease on baseline MRI was characterized. Site of initial relapse was characterized as purely local (involving/adjacent to initial site) vs distan

APA, Harvard, Vancouver, ISO, and other styles

28

Kumar, Rahul, Maximilian Deng, Kyle Smith, et al. "PATH-54. MULTI-DIMENSIONAL MOLECULAR CHARACTERIZATION OF PATIENT-MATCHED MEDULLOBLASTOMA AT DIAGNOSIS AND RELAPSE." Neuro-Oncology 21, Supplement_6 (2019): vi155. http://dx.doi.org/10.1093/neuonc/noz175.649.

Full text

Abstract:

Abstract INTRODUCTION Recurrent medulloblastoma (MB) confers an abysmal prognosis with ~10% 5-year overall survival. Optimal treatment paradigms for relapsed disease are largely unknown. Conservation of molecular subgroup at relapse has been described and divergent clonal evolution implicated, yet multi-dimensional molecular characterization of larger cohorts are warranted to substantiate these findings and to disclose potential mechanisms underlying treatment failure and disease recurrence. METHODS A multi-institutional series of 85 patient-matched, primary MBs and their relapses was profiled

APA, Harvard, Vancouver, ISO, and other styles

29

Hansen, M., and C. Hahn. "P.027 Autoimmune encephalitis: modifiable and non-modifiable predictors of relapse." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 50, s2 (2023): S65. http://dx.doi.org/10.1017/cjn.2023.131.

Full text

Abstract:

Background: Approximately 25% of encephalitis cases in North America are autoimmune (AIE). For most forms of AIE, it is unclear which patients have the highest relapse risk and whether standard treatments reduce this risk. Our objective was to determine the overall risk of relapse and whether chronic immunosuppressive therapy modifies that risk. Methods: We performed a chart review consisting of all patients with AIE presenting to the Calgary Neuro-Immunology Clinic and Tom Baker Cancer Centre between 2015 and 2020. Predictors of relapse were determined with use of t-test. Results: Outcome dat

APA, Harvard, Vancouver, ISO, and other styles

30

Oki, Yasuhiro, Dai Chihara, Yoshitoyo Kagami, et al. "Patterns of Relapse and Value of Follow up Procedures in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Achieve a Complete Remission (CR)." Blood 112, no. 11 (2008): 5306. http://dx.doi.org/10.1182/blood.v112.11.5306.5306.

Full text

Abstract:

Abstract Purpose: Optimal follow up schedule and choice of diagnostic modalities have not been well studied in patients with DLBCL who achieve CR after initial treatment. We analyzed patterns of relapse in patients with DLBCL who were treated with CHOP±R therapy and achieved CR in our institution between 1999 and 2007. We generally follow such patients with physical exam and blood tests including LDH every 3 months and CT scans every 3 to 6 months for the first two years. Follow up schedule varied afterwards. Patients and methods: Thirty-eight patients experienced relapse, in whom we first det

APA, Harvard, Vancouver, ISO, and other styles

31

Absi, Ahmed, Brian J. Bolwell, Ronald Sobecks, et al. "High Incidence of Extramedullary Relapses Following Allogeneic Bone Marrow Transplant (Allo-BMT) in Adults with Acute Lymphoblastic Leukemia." Blood 104, no. 11 (2004): 5117. http://dx.doi.org/10.1182/blood.v104.11.5117.5117.

Full text

Abstract:

Abstract Allo-BMT represents a curative therapy for certain patients with ALL. Unfortunately, leukemia relapse still represents a major problem following allo-BMT. Studying the pattern of relapses following allo-BMT may shed some light into the exact mechanisms of such relapses and suggest better ways to prevent them. Extramedullary relapses have been reported following allo-BMT for ALL. We investigated the pattern of ALL relapses in 57 patients after allo-BMT. All donors were HLA matched serologically at HLA A, B, and DR. All patients were treated with high-dose busulfan (16 mg/kg) combined w

APA, Harvard, Vancouver, ISO, and other styles

32

Kalinina, I. I., D. A. Venyov, O. V. Goronkova, et al. "Treatment results of children and adolescents with relapsed AML who were initially treated according to the AML-MM-2006 protocol." Russian journal of hematology and transfusiology 68, no. 2 (2023): 152–65. http://dx.doi.org/10.35754/0234-5730-2023-68-2-152-165.

Full text

Abstract:

Introduction. Relapse of acute myeloid leukemia (AML) develops in children who received intensive chemotherapy and achieved the first complete remission (CR1). Only intensive anti-relapse chemotherapy followed by allogeneic hematopoietic cell transplantation (allo-HSCT) may lead to cure.Aim — to present the results of treatment of children with AML who relapsed after completion of treatment or while on therapy according to the AML-MM-2006 protocol.Materials and methods. The study included children with AML who relapsed after completion of treatment of the first-line therapy according to the AM

APA, Harvard, Vancouver, ISO, and other styles

33

Shimoni, Avichai, Avital Rand, Izhar Hardan, et al. "Isolated Extra-Medullary Relapse of Acute Leukemia after Allogeneic Stem-Cell Transplantation; Different Kinetics and Better Prognosis Than Systemic Relapse." Blood 112, no. 11 (2008): 2148. http://dx.doi.org/10.1182/blood.v112.11.2148.2148.

Full text

Abstract:

Abstract Allogeneic stem-cell transplantation (SCT) is a potentially curative treatment for acute leukemia, however relapsing disease is the major cause of treatment failure after SCT. Isolated extramedullary relapse is considered a rare event and its characteristics and prognosis are less defined than in systemic relapse. We analyzed outcomes of 356 consecutive patients (pts) with AML/MDS (n=277) and ALL (n=79) given SCT over an 8-year period in a single institution. This was a relatively high-risk group with only 34% of pts been in CR1. 68% of transplants were myeloablative, 54% of the donor

APA, Harvard, Vancouver, ISO, and other styles

34

Vose, Julie M., John C. Chan, Philip J. Bierman, et al. "Relapse from Complete Remission More Than 5 Years after Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Relapse Histology Most Commonly DLBCL with a Germinal Center B-Cell (GCB) Phenotype." Blood 110, no. 11 (2007): 3430. http://dx.doi.org/10.1182/blood.v110.11.3430.3430.

Full text

Abstract:

Abstract Although many patients are successfully treated for DLBCL, relapses can occur especially in the higher risk patients. Relapses in successfully treated DLBCL patients most frequently occur within the first 2–3 years. However in a small number of patients, relapses occurring after 5 years do happen and have been frequently reported to be a relapse of follicular lymphoma. We evaluated 805 patients with DLBCL treated with an anthracycline based chemotherapy through the Nebraska Lymphoma Study Group from 1983–1998. The patients were treated prior to the use of rituximab in this patient pop

APA, Harvard, Vancouver, ISO, and other styles

35

KÄLSCH, ANNA-ISABELLE, ELENA CSERNOK, DOMINIK MÜNCH, et al. "Use of Highly Sensitive C-Reactive Protein for Followup of Wegener’s Granulomatosis." Journal of Rheumatology 37, no. 11 (2010): 2319–25. http://dx.doi.org/10.3899/jrheum.100302.

Full text

Abstract:

Objective.Since Wegener’s granulomatosis (WG) represents a relapsing disease, efforts have been made to reliably predict relapses using blood tests. Followup measures such as conventionally determined C-reactive protein (CRP), antineutrophil cytoplasmic antibody (C-ANCA) titer, and proteinase-3 (PR3) ELISA are applied. We evaluated whether during remission elevated highly sensitive CRP (hsCRP) precedes relapse as a marker of subclinical inflammation and thus might improve clinical assessment.Methods.We investigated 227 sera of 57 patients with WG: 74 sera collected from patients in remission w

APA, Harvard, Vancouver, ISO, and other styles

36

Lee, A. Y., J. M. Connors, P. Klimo, S. E. O'Reilly, and R. D. Gascoyne. "Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B." Journal of Clinical Oncology 15, no. 5 (1997): 1745–53. http://dx.doi.org/10.1200/jco.1997.15.5.1745.

Full text

Abstract:

PURPOSE To examine the clinical course of patients who experienced a late relapse after initial curative chemotherapy for advanced-stage diffuse large-cell lymphoma. PATIENTS AND METHODS Between April 1981 and June 1986, 127 patients with de novo advanced-stage diffuse large-cell lymphoma were treated with a 12-week chemotherapy program (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin [MACOP-B]). The overall survival rate at 10 years is 52%. One hundred six patients (83%) entered a complete remission (CR) and 43 of them relapsed. With a median follow-up dura

APA, Harvard, Vancouver, ISO, and other styles

37

Romano, Emanuela, Michael Scordo, Stephen W. Dusza, Daniel G. Coit, and Paul B. Chapman. "Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines." Journal of Clinical Oncology 28, no. 18 (2010): 3042–47. http://dx.doi.org/10.1200/jco.2009.26.2063.

Full text

Abstract:

Purpose Stage III melanoma is associated with a high risk of relapse and mortality. Nevertheless, follow-up guidelines have largely been empirical rather than evidence-based. Patients and Methods Clinical records of stage III patients with no evidence of disease seen at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1992 and 2004, who ultimately relapsed, were reviewed retrospectively to evaluate date of first relapse, time to first relapse, method of first relapse detection, and survival. We also determined overall 5-year relapse-free survival (RFS) of all stage III patients seen at M

APA, Harvard, Vancouver, ISO, and other styles

38

Douer, Dan, Lynette Zickl, Charles A. Schiffer, et al. "Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129." Blood 118, no. 21 (2011): 83. http://dx.doi.org/10.1182/blood.v118.21.83.83.

Full text

Abstract:

Abstract Abstract 83 The European APL91 and the North American Intergroup study I0129 reported in the 1990s that ATRA combined with chemotherapy markedly improves the outcome of APL. Large randomized and single arm studies from around the world with both short and relatively long-term follow-up, confirm this impact of ATRA, while optimizing their mode of administration. However, the incidence and outcome of late relapses have not been well established. Furthermore, as strategies to minimize or eliminate chemotherapy by combining ATRA and arsenic trioxide are being adopted, the long-term durabi

APA, Harvard, Vancouver, ISO, and other styles

39

Szela, Joel, Angy Hanna, and Matthew Sims. "2419. Timing of Secondary Prophylaxis Against Clostridium difficile Infection After Antibiotic Exposure." Open Forum Infectious Diseases 6, Supplement_2 (2019): S835. http://dx.doi.org/10.1093/ofid/ofz360.2097.

Full text

Abstract:

Abstract Background Clostridium difficile infection (CDI) is the most common nosocomial infection, and is increasing. The major risk for CDI is antibiotic (abx) use. We have previously shown that secondary prophylaxis with vancomycin decreases CDI relapse in patients with recent CDI given abx to treat another infection. The median time to relapse after use of abx was 3 days. In an effort to further elucidate the best way to employ secondary prophylaxis against CDI, we examined all patients with CDI in our institution in 2016 and timing of relapse as related to another exposure to abx and the s

APA, Harvard, Vancouver, ISO, and other styles

40

Schönau, V., G. Corte, S. Ott, et al. "POS0809 CHARACTERIZATION OF RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS (GCA) PATIENTS- DATA FROM THE REAL-LIFE TREATMENT AND SAFETY (REATS)-GCA COHORT." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 694.1–694. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3543.

Full text

Abstract:

BackgroundGiant cell arteritis (GCA) has the tendency to relapse once treatment is tapered or stopped. Such relapses represent a potential threat to GCA patients as they can lead to severe symptoms and organ damage.ObjectivesTo assess the frequency and type of relapses in patients with GCAMethodsThe Real-Life Treatment and Safety (REATS)-GCA cohort has been established by extracting the data on clinical presentation, inflammatory markers, imaging, comorbidities, treatments and serious adverse events of GCA patients from 6 specialized centres in Germany. We undertook descriptive and survival an

APA, Harvard, Vancouver, ISO, and other styles

41

Wang, Yucai, Umar Farooq, Brian K. Link, et al. "Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era." Blood 132, Supplement 1 (2018): 454. http://dx.doi.org/10.1182/blood-2018-99-113213.

Full text

Abstract:

Abstract Introduction: The addition of Rituximab to chemotherapy has significantly improved the outcome of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Patients treated with immunochemotherapy for DLBCL who achieve EFS24 (event-free for 2 years after diagnosis) have an overall survival equivalent to that of the age- and sex-matched general population. Relapses after achieving EFS24 have been considered to be unusual but have been understudied. We sought to define the rate, clinical characteristics, treatment pattern, and outcomes of such relapses. Methods: 1448 patients

APA, Harvard, Vancouver, ISO, and other styles

42

Kapke, Jonathan, Narendranath Epperla, Namrata Shah, et al. "Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)." Blood 126, no. 23 (2015): 3169. http://dx.doi.org/10.1182/blood.v126.23.3169.3169.

Full text

Abstract:

Abstract Background: It is common for classical Hodgkin lymphoma (cHL) patients following auto-HCT to undergo surveillance imaging to monitor for disease progression or relapse. Although post auto-HCT surveillance imaging is employed at most centers, the literature remains unclear on how this practice affects overall survival. Furthermore, surveillance imaging results in significant amounts of radiation exposure as well as invasive procedures to work up false positive findings. We studied cHL patients who underwent auto-HCT at three transplant centers to define how many surveillance imaging st

APA, Harvard, Vancouver, ISO, and other styles

43

Cohen-Gogo, Sarah, Allen Buxton, Natalie DelRocco, et al. "Survival and prognostic factors of patients with Ewing sarcoma at first recurrence following modern era multimodal therapy: A report from the Children’s Oncology Group (COG)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 10035. https://doi.org/10.1200/jco.2025.43.16_suppl.10035.

Full text

Abstract:

10035 Background: Ewing sarcoma (EwS) is a rare malignancy of children, adolescents and young adults for which outcomes have progressively improved through intensification of conventional chemotherapy, including interval compression of cycles. Prior cooperative group reports of relapsed EwS included patients treated less intensively and with fewer treatment options at relapse. Here, we report overall survival (OS) and prognostic factors post-first recurrence in patients with EwS treated with frontline interval-compressed chemotherapy. Methods: We included patients treated on the last three pha

APA, Harvard, Vancouver, ISO, and other styles

44

Ortega, J. A., M. E. Nesbit, H. N. Sather, L. L. Robison, G. J. D'Angio, and G. D. Hammond. "Long-term evaluation of a CNS prophylaxis trial--treatment comparisons and outcome after CNS relapse in childhood ALL: a report from the Childrens Cancer Study Group." Journal of Clinical Oncology 5, no. 10 (1987): 1646–54. http://dx.doi.org/10.1200/jco.1987.5.10.1646.

Full text

Abstract:

The current status of children with acute lymphoblastic leukemia (ALL) who had developed CNS disease while being treated on protocol CCG-101 was investigated. Seven hundred thirty-six eligible patients were entered into the study between June 1972 and July 1974. All children who were greater than 18 months of age were eligible for randomization to a CNS prophylaxis trial for which one regimen gave only a short course of intrathecal methotrexate (IT MTX) as prophylaxis. All other regimens included radiation therapy as prophylaxis. Current follow-up (median, greater than 10 years) shows no signi

APA, Harvard, Vancouver, ISO, and other styles

45

Fossard, Gaelle, Emmanuelle Nicolas-Virelizier, Philippe Rey, et al. "Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse." Blood 122, no. 21 (2013): 933. http://dx.doi.org/10.1182/blood.v122.21.933.933.

Full text

Abstract:

Abstract Introduction The optimal follow-up strategy for primary CNS lymphoma (PCNSL) patients in remission after first line therapy is not clear. The goal of this study is to determine the utility of planned brain surveillance imaging in the detection of relapse in a large cohort of PCNSL patients. Methods Patients were from consecutive PCNSL cases (N=209) included in Leon Berard Cancer Centre registry (Lyon, France), from 1987 to 2011 (date of diagnosis). Patients were all treated by chemotherapy, 92% of them by high-dose methotrexate containing chemotherapy followed by brain radiotherapy fo

APA, Harvard, Vancouver, ISO, and other styles

46

Yamasaki, Kai, Kazuki Tanimura, Yuki Okuhiro, et al. "MBCL-22. EFFICACY OF DOUBLE-CONDITIONING REGIMEN COMPRISING THIOTEPA AND MELPHALAN FOR RELAPSED MEDULLOBLASTOMA – A SINGLE INSTITUTION EXPERIENCE." Neuro-Oncology 22, Supplement_3 (2020): iii393. http://dx.doi.org/10.1093/neuonc/noaa222.498.

Full text

Abstract:

Abstract BACKGROUND The prognosis of relapsed medulloblastoma was dismal. Recently, we published the promising outcome of metastatic medulloblastomas treated with a double-conditioning regimen comprising high-dose thiotepa and melphalan (HD-TM). Here, we report a single-center study of HD-TM for relapsed medulloblastomas. MATERIALS AND METHODS From April 2006 to January 2019, 17 consecutive medulloblastoma patients with the first relapse were identified, and of which 10 received HD-TM were retrospectively reviewed. RESULTS The median age at first relapse was 11.9 years (range 1.8–31.7). The me

APA, Harvard, Vancouver, ISO, and other styles

47

Weeks, J. C., B. Y. Yeap, G. P. Canellos, and M. A. Shipp. "Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission." Journal of Clinical Oncology 9, no. 7 (1991): 1196–203. http://dx.doi.org/10.1200/jco.1991.9.7.1196.

Full text

Abstract:

Salvage therapy for relapsed large-cell lymphoma (LCL) is more effective in patients with minimal disease, suggesting that early detection of relapse might increase the chance of long-term survival. To determine whether current follow-up procedures are effective in identifying preclinical disease, we analyzed patterns of relapse in 139 LCL patients who achieved a complete remission (CR) with high/moderate-dose methotrexate with leucovorin, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (M/m-BACOD). The timing and results of all posttreatment follow-up tests were exami

APA, Harvard, Vancouver, ISO, and other styles

48

Moerdler, Scott, Arlene Naranjo, Sheena Tenney, Rochelle Bagatell, Alice L. Yu, and Wendy B. London. "Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma." Journal of Clinical Oncology 40, no. 16_suppl (2022): 10043. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.10043.

Full text

Abstract:

10043 Background: While the addition of anti-GD2 immunotherapy led to improvement in outcomes in patients on the Children’s Oncology Group (COG) ANBL0032 study, relapse remains a concern. Prior studies demonstrated the prognostic importance of time to first relapse, however, the effect of immunotherapy on timing and patterns of relapse in neuroblastoma (NBL) have yet to be evaluated. The purpose of this exploratory analysis was to describe the impact of immunotherapy on patterns of relapse in patients with high-risk NBL, including a descriptive comparison of sites of relapse based on post-cons

APA, Harvard, Vancouver, ISO, and other styles

49

Moerdler, Scott, Arlene Naranjo, Sheena Tenney, Rochelle Bagatell, Alice L. Yu, and Wendy B. London. "Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma." Journal of Clinical Oncology 40, no. 16_suppl (2022): 10043. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.10043.

Full text

Abstract:

10043 Background: While the addition of anti-GD2 immunotherapy led to improvement in outcomes in patients on the Children’s Oncology Group (COG) ANBL0032 study, relapse remains a concern. Prior studies demonstrated the prognostic importance of time to first relapse, however, the effect of immunotherapy on timing and patterns of relapse in neuroblastoma (NBL) have yet to be evaluated. The purpose of this exploratory analysis was to describe the impact of immunotherapy on patterns of relapse in patients with high-risk NBL, including a descriptive comparison of sites of relapse based on post-cons

APA, Harvard, Vancouver, ISO, and other styles

50

Herrity, Elizabeth Kathryn, Tommy Alfaro, Mariana Pinto Pereira, et al. "Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome." Blood 142, Supplement 1 (2023): 2206. http://dx.doi.org/10.1182/blood-2023-187145.

Full text

Abstract:

Introduction Allogeneic hematopoietic stem cell transplantation (HCT) is a curative therapy used to treat myelodysplastic syndrome (MDS). Relapse post-HCT confers poor outcomes and subsequent therapy is not standardized. Like acute myeloid leukemia (AML), several mechanisms are known to be involved in post-HCT relapse including clonal evolution in favor of chemotherapy-resistant clones and tumor immune escape. Systemic reviews are scarce in the MDS post-HCT relapse population. Accordingly, the present study aimed to investigate clinical, cytogenetic, and immunophenotypic (IP) spectra for MDS p

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!